Taking a Closer Look at Unevenly Charged Biomolecules
August 22, 2018 | AIP.orgEstimated reading time: 1 minute
In clinical diagnostics, it is critical to monitor biomolecules in a simple, rapid and sensitive way. Clinicians most often monitor antibodies because these small proteins attach to antigens, or foreign substances, we face every day. Most biomolecules, however, have complicated charge characteristics, and the sensor response from conventional carbon nanotube systems can be erratic. A team in Japan recently revealed how these systems work and proposed changes to dramatically improve biomolecule detection.
These researchers demonstrated a new technique to detect, measure and analyze biomolecules with inhomogeneous charge distributions by adjusting the solution in which they monitor the biomolecule. They used carbon nanotube thin film transistors (CNT-TFTs) to zero in on the precise amount of a specific biomolecule is in a specimen.
CNT-TFT biosensors use immune antibody receptors called aptamers to detect the net electric charge of the part of the target molecule. After scientists identify a molecule, an antibody is made to attach to it in solution. That antibody then connects to an aptamer on a thin film of carbon nanotubes that converts the connection into an electrical signal for sensor detection. With this enhanced sensor response, researchers can determine the Debye length, or the distance between a point charge and the molecule, to map out a molecule’s uneven charge distributions.
The group discovered that they had to look at how the charges were distributed close to a molecule’s surface to understand the complicated behavior in the sensor signal. “Despite being the same target molecule, the polarities of the sensor response are completely different from positive or negative,” said Ryota Negishi, an author on the paper.
“We achieved the improvement of dynamic range by using low concentration of buffer solution,” Negishi said. “As a result, we clarified the mechanism of complicated sensor response which has not been clarified in previous reports.”
Many different features of an experiment can affect a molecule’s Debye length, so these results show promise for further controlling sensors and modifying their dynamic range.
Next, Negishi and his colleagues hope to find a way to use their findings in more real-life scenarios. “For practical application, it is essential to develop a sensing technology that can be detected under high concentration conditions close to blood.”
Suggested Items
Arrow Electronics Launches Intelligent Vision Ecosystem
03/27/2024 | BUSINESS WIREArrow Electronics, Inc. is utilizing the onsemi Imager Access System (IAS) module standard for developing intelligent vision solutions for use in robotics, machine vision, commercial cameras and other uses.
onsemi Aligns Business Groups to Expand Product Portfolio and Accelerate Growth
03/13/2024 | onsemionsemi announced the formation of the Analog and Mixed-Signal Group (AMG) which will be led by newly appointed group president, Sudhir Gopalswamy.
Teledyne to Acquire Valeport
03/13/2024 | TeledyneTeledyne Technologies Incorporated announced that it has entered into an agreement to acquire Valeport Holdings Limited and its affiliates.
Cadence Expands Tensilica Vision Family with Radar Accelerator and New DSPs Optimized for Automotive Applications
03/04/2024 | Cadence Design Systems, Inc.Cadence Design Systems, Inc. expanded its Tensilica IP portfolio to address the increasing computational requirements associated with automotive sensor fusion applications.
Happy’s Tech Talk #25: Lab-on-PCBs for Medical Diagnosis
02/21/2024 | Happy Holden -- Column: Happy’s Tech TalkCOVID-19 created a rush for simple and quick medical diagnostic tests for the public. Biomedical MEMS (bioMEMS) have emerged as a subset of MEMS devices for applications in biomedical research and medical microdevices, with an emphasis on mechanical parts and microfabrication technologies. Applications include disease detection, chemical monitoring, and drug delivery. There has been rapid market growth for bioMEMS technologies, and many bioMEMS devices are already commercially available. There is great potential for large-scale commercialization of microfluidic-based LoC and LoPCB technologies.